rhTNFαDa

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NamerhTNFαDa
Drug Alias NameRecombined human tumor necrosis factor-α derivative (Shanghai Fudan Biotech)rhTNFα-DarhTNFαDa
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant cytokines
Mechanisms of ActionTumor necrosis factor receptor modulators
TargetsTumor necrosis factor receptor
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPending (NDA/BLA)
Highest Status in ChinaPending
Originator CompaniesShanghai Fudan Bio-Engineering Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesN/A
Inactive CompaniesShanghai Fudan Bio-Engineering Co Ltd
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A